We are Sorry, This Page doesn't Exist

Rolling NDA submission for CUTX-101 for the treatment of Menkes disease is expected to begin in the second half of 2021 On track to report top-line results from the registration-enabling study of cosibelimab in metastatic cutaneous squ.....»»

        - First Patient Dosed in Phase 1 AL102 Combination Trial with Novartis' Anti-BCMA Agent for the Treatment of Multiple Myeloma - - On Track to Initiate AL102 Phase 2/3 Pivotal Trial for the Treatment of.....»»

Biogen Inc (NASDAQ: BIIB) has announced topline results from the Phase 2/3 XIRIUS study evaluating cotoretigene toliparvovec (BIIB112), a gene therapy being investigated as a one-time therapy for patients w.....»»

Interim futility analysis from the Phase 3 DISRUPT study of exebacase evaluating treatment superiority is anticipated in H2 2021 BARDA contract award provides up to $86.8 million for exebacase development Strong fi.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Vertex Pharmaceuticals Inc. said Tuesday it plans to pay $1.1 billion to Crispr Therapeutics AG as part of a deal to test an experimental gene-editing therapy for sickle cell disease and transfusion-dependent beta-tha.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Eli Lilly & Co. and Incyte Corp. said Thursday a Phase 3 trial of rheumatoid arthritis treatment .....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) announced results from a dose-ranging trial evaluating BCX9930 in treatment-naïve paroxysmal nocturnal hemoglobinuria read more.....»»

Incyte Corporation NASDAQ: INCY) announced results from the Phase 3 DEVENT study evaluating two doses of ruxolitinib (5mg and 15mg) plus standard of care (SoC) versus SoC in patients read more.....»»

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: read more.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

STOCKHOLM, Feb. 26, 2021 /PRNewswire/ -- "Safety data has been presented from the ongoing Phase I study with ATOR-1017 in patients with metastatic cancer. The results show a promising safety profile w.....»»

Shares of GlaxoSmithKline were down 0.2% in trading on Thursday after the drug maker said its experimental monoclonal antibody treatment did not meet the primary endpoint in a mid-stage trial evaluating its use in hospitalized COVID-19 patients of all a.....»»

A new study suggests that transplanting fecal matter into the guts of melanoma patients could help them respond better to immunotherapy. Fecal transplants, which are made up of poop an.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»